A well-groomed 'inside-outsider' – GSK's new CEO, Emma Walmsley

20 September 2016
emma-walmsley-big

GlaxoSmithKline’s decision to appoint Emma Walmsley as chief executive is a clear commitment to past strategy but an acknowledgement that a fresh, and arguably more commercially astute, approach is required to return the company to growth.

Walmsley represents an insider with an established internal track record of success and an understanding of how to get things done, but with a valuable external point of view on the weaknesses of the pharmaceuticals business gained through experiences at L’Oreal and latterly as the leader of GSK’s consumer healthcare division where she has been since 2010.

The choice of an insider signals renewed commitment to the volume-first growth strategy launched by GSK in 2015, a plan borne out of a belief that the current sky-high pricing model in pharmaceuticals is unsustainable in the long run. Industry analysts and investors were initially critical, especially given GSK’s recent performance, but the mood has warmed to the notion that large volume sales in vaccines and over the counter (OTC) products offer an attractive revenue cushion to the more risk-reward pharma division.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical